Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Timed sequential chemotherapy for advanced acute myeloid leukemia

E Archimbaud1, V Leblond, P Fenaux

  • 1Service d'Hématologie, Hôpital Edouard Herriot, Lyon, France.

Hematology and Cell Therapy
|April 1, 1996
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Transient ischemic attack care pathways in stroke units: Findings from a French nationwide survey.

Revue neurologique·2025
Same author

Tenecteplase in acute ischemic stroke: Review of the literature and expert consensus from the French Neurovascular Society.

Revue neurologique·2022
Same author

Safety and outcome of mechanical thrombectomy in ischaemic stroke related to carotid artery dissection.

Journal of neurology·2021
Same author

Impact of recanalisation by mechanical thrombectomy in mild acute ischemic stroke with large anterior vessel occlusion.

Revue neurologique·2021
Same author

Career aspirations among specialty residents in France: a cross-sectional gender-based comparison.

BMC medical education·2021
Same author

The impact of anti-mould prophylaxis on Aspergillus PCR blood testing for the diagnosis of invasive aspergillosis.

The Journal of antimicrobial chemotherapy·2020

Timed sequential chemotherapy (TSC) achieved complete remission in 61% of advanced acute myelogenous leukemia (AML) patients. Some relapsed patients experienced prolonged disease-free survival (DFS) with chemotherapy alone.

Area of Science:

  • Hematology
  • Oncology
  • Clinical Trials

Background:

  • Advanced acute myelogenous leukemia (AML) presents a significant treatment challenge.
  • Optimizing chemotherapy regimens is crucial for improving patient outcomes.

Purpose of the Study:

  • To evaluate the efficacy and toxicity of Timed Sequential Chemotherapy (TSC) in patients with advanced AML.
  • To assess factors influencing complete remission (CR), disease-free survival (DFS), and overall survival.

Main Methods:

  • A cohort of 240 patients with advanced AML received TSC (mitoxantrone, etoposide, cytarabine).
  • Complete remission rates, toxicity, and survival outcomes were analyzed.
  • Multivariate analysis identified prognostic factors.

Related Experiment Videos

Main Results:

  • 61% of patients achieved CR (47% refractory, 78% relapsed).
  • Median survival was 7 months; 5-year survival was 13%. Median DFS was 9 months; 5-year DFS was 13%.
  • Refractoriness was a poor prognostic factor; post-remission therapy did not significantly impact DFS.

Conclusions:

  • TSC is an effective regimen for achieving CR in advanced AML, particularly in relapsed patients.
  • Chemotherapy alone can lead to prolonged DFS in some patients with first relapse.
  • Patient refractoriness is a key determinant of prognosis.